{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,25]],"date-time":"2024-12-25T05:17:00Z","timestamp":1735103820728,"version":"3.32.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>We sought to compare our results of patients treated with Cs-131 prostate brachytherapy (PB) as monotherapy to recently published results of patients treated with stereotactic body radiotherapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We analyzed data from patients treated at our institution with Cs-131 PB as monotherapy who had at least 5 years of follow-up and who prospectively completed expanded prostate cancer index composite questionnaires at baseline, 1 year, 2 years, and 5 years. We compared our data with the recently published data from radiation therapy oncology group (RTOG) 0938 and PACE-B (NCT01584258).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 138 patients were included in our cohort. Using RTOG 0938\u2019s definition, the frequency of a decline in urinary function in our PB cohort was 43% compared with 41.3% in RTOG 0938. According to PACE-B\u2019s definition, our PB cohort had minimal clinically important differences in the urinary incontinence domain of 26.4% and in the urinary obstructive\/irritative domain of 40.7% at 2 years compared with PACE-B\u2019s reported rate of 32% and 33%, respectively. The frequency of a &gt;5-point change in the expanded prostate cancer index composite bowel summary score at 5 years was 25% compared with 30.7% in RTOG 0938. Our bowel difference at 2 years was 23% compared with PACE-B\u2019s reported 24%. Our 5-year biochemical disease free survival (bDFS) was 97.8%, compared with 91.3% in RTOG 0938 and 95.8% in PACE-B.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Low dose rate (LDR) PB with Cs-131 as monotherapy provides excellent biochemical control of prostate cancer in low and intermediate-risk patients. Our cohort of patients had modest differences in patient-reported urinary and bowel quality of life compared with baseline. These differences were comparable to recently published stereotactic body radiotherapy data. When comparing prostate cancer treatments in terms of patient convenience and available resources, PB certainly should be considered.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/coc.0000000000001145","type":"journal-article","created":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T13:02:04Z","timestamp":1729170124000},"page":"34-37","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Prostate Brachytherapy With Cs-131"],"prefix":"10.1097","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3063-8991","authenticated-orcid":false,"given":"Ryan P.","family":"Smith","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, UPMC Hillman Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed A.","family":"Mohammed","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, UPMC Hillman Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sushil","family":"Beriwal","sequence":"additional","affiliation":[{"name":"Allegheny Health Network"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald M.","family":"Benoit","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Pittsburgh Medical Center, Pittsburgh, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,10,17]]},"reference":[{"key":"R2-20241224","doi-asserted-by":"crossref","first-page":"134","DOI":"10.6004\/jnccn.2021.0008","article-title":"NCCN guidelines insights: prostate cancer, version 1.2021","volume":"19","author":"Schaeffer","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"suppl 1","key":"R3-20241224","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1464-410X.2011.10827.x","article-title":"Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group","volume":"109","author":"Grimm","year":"2012","journal-title":"BJU Int"},{"key":"R4-20241224","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1200\/JCO.2016.72.0466","article-title":"Brachytherapy for patients with prostate cancer: American Society of Clinical Oncology\/Cancer Care Ontario joint guideline update","volume":"35","author":"Chin","year":"2017","journal-title":"J Clin Oncol"},{"key":"R5-20241224","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.brachy.2020.02.006","article-title":"Cesium-131 prostate brachytherapy: a single institutional long-term experience","volume":"19","author":"Benoit","year":"2020","journal-title":"Brachytherapy"},{"key":"R6-20241224","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.eururo.2019.10.030","article-title":"Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the protect randomised controlled trial according to treatment received","volume":"77","author":"Neal","year":"2020","journal-title":"Eur Urol"},{"key":"R7-20241224","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.eururo.2017.06.035","article-title":"Quality of life outcomes after primary treatment for clinically localised prostate cancer: a systematic review","volume":"72","author":"Lardas","year":"2017","journal-title":"Eur Urol"},{"key":"R8-20241224","doi-asserted-by":"crossref","first-page":"430.e1","DOI":"10.1016\/j.urolonc.2016.04.015","article-title":"Acute and late urinary toxicity following radiation in men with an intact prostate gland or after a radical prostatectomy: a secondary analysis of RTOG 94-08 and 96-01","volume":"34","author":"Mak","year":"2016","journal-title":"Urol Oncol"},{"key":"R9-20241224","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.brachy.2015.12.011","article-title":"Predictive factors for urinary toxicity after iodine-125 prostate brachytherapy with or without supplemental external beam radiotherapy","volume":"15","author":"Eriguchi","year":"2016","journal-title":"Brachytherapy"},{"key":"R10-20241224","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.radonc.2013.08.030","article-title":"Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials","volume":"109","author":"King","year":"2013","journal-title":"Radiother Oncol"},{"key":"R11-20241224","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ijrobp.2018.06.008","article-title":"Patient reported outcomes in NRG oncology RTOG 0938, evaluating two ultrahypofractionated regimens for prostate cancer","volume":"102","author":"Lukka","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R12-20241224","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.ijrobp.2022.12.022","article-title":"Five-year patient-reported outcomes in NRG oncology RTOG 0938, evaluating two ultrahypofractionated regimens for prostate cancer","volume":"116","author":"Lukka","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R13-20241224","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","article-title":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","volume":"23","author":"Tree","year":"2022","journal-title":"Lancet Oncol"},{"key":"R14-20241224","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.ijrobp.2023.08.027","article-title":"5-year outcomes from PACE B: an international phase III randomized controlled trial comparing stereotactic body radiotherapy (SBRT) vs. conventionally fractionated or moderately hypo fractionated external beam radiotherapy for localized prostate cancer","volume":"117","author":"van As","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R15-20241224","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.brachy.2008.04.003","article-title":"Planning based on postneedle volume with early dosimetric assessment is beneficial for Cesium-131 permanent prostate seed implantation","volume":"7","author":"Smith","year":"2008","journal-title":"Brachytherapy"},{"key":"R16-20241224","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.brachy.2023.08.009","article-title":"Redefining bladder neck dose in low-dose-rate prostate brachytherapy\u2014can we improve urinary toxicity without impacting disease control?","volume":"23","author":"Koerner","year":"2024","journal-title":"Brachytherapy"},{"key":"R17-20241224","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa074311","article-title":"Quality of life and satisfaction with outcome among prostate-cancer survivors","volume":"358","author":"Sanda","year":"2008","journal-title":"N Engl J Med"},{"key":"R18-20241224","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0090-4295(00)00858-X","article-title":"Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer","volume":"56","author":"Wei","year":"2000","journal-title":"Urology"},{"key":"R19-20241224","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/JCO.2002.20.2.557","article-title":"Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer","volume":"20","author":"Wei","year":"2002","journal-title":"J Clin Oncol"},{"key":"R20-20241224","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.urology.2014.08.044","article-title":"Minimally important difference for the expanded prostate cancer index composite short form","volume":"85","author":"Skolarus","year":"2015","journal-title":"Urology"},{"key":"R21-20241224","doi-asserted-by":"crossref","first-page":"5078","DOI":"10.1200\/JCO.2007.11.4645","article-title":"Lessons learned in the assessment of health-related quality of life: selected examples from the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Brundage","year":"2007","journal-title":"J Clin Oncol"},{"key":"R22-20241224","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.radonc.2015.07.016","article-title":"Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy","volume":"116","author":"Evans","year":"2015","journal-title":"Radiother Oncol"},{"key":"R23-20241224","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1002\/cncr.30519","article-title":"Predictors of multidomain decline in health-related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer","volume":"123","author":"Dess","year":"2017","journal-title":"Cancer"},{"key":"R24-20241224","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.urology.2009.12.084","article-title":"Acute lower urinary tract symptoms after prostate brachytherapy with cesium-131","volume":"76","author":"Jacobs","year":"2010","journal-title":"Urology"},{"key":"R25-20241224","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.brachy.2009.09.006","article-title":"Clinical and dosimetric factors associated with acute rectal toxicity in patients treated with (131)Cs brachytherapy for prostate cancer","volume":"9","author":"Gokhale","year":"2010","journal-title":"Brachytherapy"},{"key":"R26-20241224","doi-asserted-by":"crossref","first-page":"e188006","DOI":"10.1001\/jamanetworkopen.2018.8006","article-title":"Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer","volume":"2","author":"Kishan","year":"2019","journal-title":"JAMA Netw Open"},{"key":"R27-20241224","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.radonc.2020.04.038","article-title":"A biochemical definition of cure after brachytherapy for prostate cancer","volume":"149","author":"Crook","year":"2020","journal-title":"Radiother Oncol"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000001145","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T08:00:17Z","timestamp":1735027217000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000001145"}},"subtitle":["Long-term Results Compared With Published Stereotactic Body Radiotherapy Data"],"short-title":[],"issued":{"date-parts":[[2024,10,17]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000001145","relation":{},"ISSN":["0277-3732","1537-453X"],"issn-type":[{"type":"print","value":"0277-3732"},{"type":"electronic","value":"1537-453X"}],"subject":[],"published":{"date-parts":[[2024,10,17]]}}}